A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study) (React-G)
Sponsor: Ottawa Hospital Research Institute
A observational or N/A phase clinical study on Early Stage Breast Cancer, this trial is completed. The trial is conducted by Ottawa Hospital Research Institute and has accumulated 7 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 2 earlier versions
-
Oct 2017 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2017 — Oct 2017 [monthly]
Recruiting NA
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ottawa Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .